Lymphoma and Myeloma

In an effort to provide comprehensive care to patients with Lymphoma and Myeloma, physicians, researchers, and other medical professionals at the University of Kansas Medical Center have developed this Lymphoma/Myeloma program website.

Our Mission: "Through cutting-edge research, develop and implement novel and effective treatments for long-term control and eradication of lymphoma any myeloma delivered in a ‘world class' patient care and educational setting of KU Cancer Center."

Clinical Trials

There are many clinical trials at the University of Kansas Cancer Center. Please select the links below to learn more

Featured Trial

• A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
  • PI: Sid Ganguly, MD
  • NCT01482962- Learn national information about this trial

Other Lymphoma and Myeloma Trials

• Hodgkin's Lymphoma
• Non-Hodgkin's Lymphoma
• Myeloma
• Clinical Trial Main Page

Support Groups

• Conquering Myeloma: Call 913-588-1227 to register
• Leukemia and Lymphoma Support Group: Call 913-588-1227 to register
• Turning Point: Support for serious or chronic physical illness in the KC area
• Gilda's Club: Support for all cancers and stages
• Cancer Action: For programs and services of persons with cancer, their family and friends  

Patient Story

The Susan Varner Story:When Susan was first admitted to The University of Kansas Cancer Center's Blood and Marrow Transplant (BMT) unit this past year, our family was immediately impressed with the knowledge, efficiency, and assurance they provided. Dr. Ganguly was not only expecting our arrival, but was already familiar with Susan's case, and instantly made us feel as though the team was in control of her situation. By the end of her first day there, we had a plan established for her treatment, and diagnostic screenings. Because of the rarity of Susan's disease, we knew we needed to be in a cutting edge facility that could offer her the most advanced options possible. Her case was treated with urgency, and expertise. We were impressed by the BMT team's willingness to consult with experts worldwide to come up with the best possible solutions for Susan. This proved to us that we were in the right place, and that Susan's case truly mattered to her doctors. To this day, we remain grateful for the matchless quality of care Susan received from her doctors and nurses during her stay in the University of Kansas Cancer Center's BMT unit. We continue to be impressed with the progress, and truly innovative research being done to improve treatments, and eradicate the effects of blood cancer at both the University of Kansas Cancer Center, and the University of Kansas Medical Center.

Contact Carol Webb, at cwebb2@kumc.edu to enter your story.